Neuren Completes Additional Phase I Study for TBI
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren reduces outstanding convertible note principal
- Neuren Completes Phase II trial Cohort 1
- Neuren Rights Issue Offer Document (NZ residents)
- Neuren Rights Issue Letter of Offer (Australian residents)
- NEU: Neuren places $3m of rights issue shortfall
Later from Neuren Pharmaceuticals
- Cato strategic partnership and appoints US CMO
- Grant funding for TFF oncology program
- Neuren Starts Phase II Trial of NNZ2566
- Trial of Second Neuren Drug Motiva to be Initiated
- Neuren awarded Rett Syndrome trial grant
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals